The FDA Modernization Act 2.0 has shifted from animal testing to New Approach Methodologies (NAMs) for preclinical drug development. Three-dimensional (3D) bioprinting has emerged as a premier NAM, ...
Neurodegenerative diseases (NDDs) present significant challenges due to limited treatment options, ethical concerns surrounding traditional animal models, and the time-consuming and costly process of ...
At TU Wien, researchers are developing three-dimensional (3D) printing techniques that can be used to create living biological tissue—for example, to study skin diseases. Roughly one-quarter of Europe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results